Suzhou, China
Ractigen Therapeutics, founded in 2017, is a clinical-stage biotech company in the Health Care and Pharmaceutical industries, headquartered in China. Known for its slogan, "Turn on genes and turn off diseases," Ractigen is at the forefront of leveraging a groundbreaking discovery dubbed RNA activation (RNAa) to design first-in-class therapies. Unlike traditional treatments, Ractigen's innovative approach selectively reactivates suppressed therapeutic genes within diseased cells, addressing a critical unmet medical need.
Since its inception in 2016 by pioneers in the field, the company has cultivated a promising pipeline of candidate medicines. In its last funding round on 27 January 2022, Ractigen secured a $30.00M Series A investment from notable investors including Eisai, LC Ventures, SDIC Ventures, Xiang He Capital, Sino-Singapore Capital, and China Singapore Suzhou Industrial Park Ventures, indicating strong confidence in its visionary mission and transformative potential.
Avidity Biosciences, Inc.
